Overview
ELOC-mutated renal cell carcinoma refers to renal cell carcinomas harboring alterations in the epigenetic regulator ELOC (also known as EZH2), which may influence treatment response and prognosis. Specific targeted therapies for ELOC mutations are emerging but not extensively covered in the provided abstracts, which focus more on KRAS G12C inhibitors.Diagnosis
Genetic testing for ELOC mutations via next-generation sequencing (NGS) panels [Not directly covered in abstracts].
Histopathological examination confirming renal cell carcinoma [Not directly covered in abstracts].
Imaging studies (CT, MRI) to assess tumor extent and metastasis [Not directly covered in abstracts].Management
First-line treatment: Limited direct evidence in abstracts; typically involves immunotherapy (e.g., PD-1 inhibitors) or targeted therapies based on broader genomic profiles [Not directly covered in abstracts].
Adjunctive treatments: Monitoring for hepatobiliary adverse events crucial if KRAS G12C inhibitors are considered off-label, given their hepatotoxicity profiles 12.Special Populations
Hepatobiliary monitoring: Essential in all patients, especially those receiving KRAS G12C inhibitors, due to increased risk of hepatic cytolysis and elevated liver enzymes 12.
Pregnancy, pediatrics, elderly: Specific guidance not provided in the abstracts [Not directly covered in abstracts].Key Recommendations
Closely monitor liver function tests in patients treated with KRAS G12C inhibitors, given the significant risk of hepatobiliary adverse events 12 (Evidence: Moderate).
Consider genetic testing for ELOC mutations to guide personalized treatment strategies, though specific therapeutic recommendations are not detailed in the provided abstracts [Not directly covered in abstracts] (Evidence: Expert opinion).
Evaluate the use of immunotherapy or other targeted therapies based on comprehensive genomic profiling, as direct evidence for ELOC-specific treatments is limited [Not directly covered in abstracts] (Evidence: Expert opinion).References
1 Frey C. Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib. Pharmacoepidemiology and drug safety 2025. link
2 Jian S, Liang S, Ma X, Chen S, Zhang X, Lan X et al.. Real-world adverse event analysis of Adagrasib: Insights from the FAERS database. Medicine 2025. link